The weekly litigation news digest is live. Subscribe now

Mesalazine Tablet Having Improved Dissolution - EP2611429

The patent EP2611429 was granted to Disphar on Feb 21, 2018. The application was originally filed on Sep 1, 2011 under application number EP11752210A. The patent is currently recorded with a legal status of "Revoked".

EP2611429

DISPHAR
Application Number
EP11752210A
Filing Date
Sep 1, 2011
Status
Revoked
Jul 10, 2020
Publication Date
Feb 21, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TILLOTTS PHARMANov 21, 2018BECK GREENER -

Patent Citations (16) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP2072043
DESCRIPTIONWO2009090484
DESCRIPTIONWO9832676
INTERNATIONAL-SEARCH-REPORTEP2072043
INTERNATIONAL-SEARCH-REPORTUS2009036414
INTERNATIONAL-SEARCH-REPORTWO2009047802
INTERNATIONAL-SEARCH-REPORTWO9826767
OPPOSITIONEP2072043
OPPOSITIONJP2008074790
OPPOSITIONUS2002068088
OPPOSITIONUS2009036414
OPPOSITIONUS4539198
OPPOSITIONUS5108758
OPPOSITIONWO2006102446
OPPOSITIONWO2009047802
OPPOSITIONWO9826767

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents